Fortrea to Acquire Worldwide Clinical Trials Early Phase Services (Clinical Pharmacology Unit & Bioanalytical Lab)

Worldwide Clinical Trials Acquires Catalyst Clinical Research

February 17, 2026

Healthcare Services

Worldwide Clinical Trials completed its acquisition of oncology CRO Catalyst Clinical Research, expanding Worldwide’s oncology capabilities, biometrics, and functional service provider (FSP) offerings. The combined organization will operate with a workforce of approximately 4,400 employees across more than 70 countries, and financial terms were not disclosed.

PhaseWell Research Acquires Bio Behavioral Health

January 21, 2026

Healthcare Services

PhaseWell Research, a national clinical research site company, announced that Bio Behavioral Health has joined its network to expand access to neuropsychiatric and CNS clinical trials. The deal strengthens PhaseWell's community-based research capabilities and broadens patient access to complex clinical studies across its growing national footprint.

Arsenal Capital Partners Acquires Endpoint Clinical and Fortrea Patient Access from Fortrea

March 11, 2024

Healthcare Services

Arsenal Capital Partners has acquired Fortrea's Endpoint Clinical and Fortrea Patient Access businesses in a divestiture completed June 4, 2024. The sale allows Fortrea to sharpen its focus as a pure‑play CRO while Arsenal will position Endpoint and the Patient Access business for accelerated investment and growth under management led by Sam Osman.

Kohlberg Acquires Majority Stake in Worldwide Clinical Trials

August 7, 2023

Healthcare Services

An affiliate of Kohlberg & Company agreed to acquire a majority stake in Worldwide Clinical Trials, a global contract research organization (CRO) headquartered in Research Triangle Park, North Carolina. The transaction is a recapitalization in which prior investor TJC, L.P. retains a meaningful minority equity stake; terms were not disclosed. Kohlberg will partner with Worldwide's management (Matt Jennings to become chairman) to support continued growth of the company's clinical trial and bioanalytical capabilities.

Altasciences Acquires WCCT Global

February 12, 2021

Healthcare Services

Altasciences acquired WCCT Global, an early‑stage clinical research organization (CRO) based in Southern California, expanding its West Coast clinical pharmacology capabilities and adding 180 clinical beds. The transaction, completed February 12, 2021, augments Altasciences’ Phase I/II services and expertise in specialized areas such as ethnobridging to support biopharmaceutical sponsors.

WCG Acquires Trifecta Clinical

December 3, 2020

Healthcare Services

WCG has acquired Trifecta Clinical, a provider of technology-enabled clinical trial site communications and training solutions including the InvestigatorSpace platform. The deal brings Trifecta's investigator training, safety letter distribution and document-exchange capabilities into WCG's suite of clinical research services while Trifecta retains its leadership and offices in Los Angeles and other locations.